John Connolly

John Connolly serves as Interim CEO at 3T Biosciences. 3T Biosciences operates in the research sector with approximately 30.0 employees. The company is headquartered in Singapore. 3T Biosciences generates annual revenue of 2000000.0. To date, 3T Biosciences has raised 52000000.0 in total funding, with the most recent round being Series A.

Industry & Role Insights

• • MessageCEO tracks 2,961 executives in the research sector.
• • We have verified contacts for 2 executives at 3T Biosciences.
• • Our database includes 201,469 c suite-level executives.

Cloudflare DNS SendInBlue Gmail Outlook Google Apps Microsoft Office 365 CloudFlare Hosting DigitalOcean Google Tag Manager Google Font API Gravity Forms Mobile Friendly WordPress.org Google Analytics Remote

biotechnology research immunotherapy t cell receptor cancer treatment target discovery therapeutic development solid tumors immune-mediated diseases machine learning 3t-trace platform patient immune responses novel targets tcr specificity tcr mimetics safer therapies effective treatments tumor-specific biotherapeutics cancer immunotherapy patient biomarkers therapeutic optimization data-driven approaches synthetic biology computational biology high-throughput screening high-diversity target libraries cross-reactivity validation toxicology screening investor partnering biopharmaceutical collaborations translational science clinical research data science bioinformatics algorithm development patient populations autoimmune diseases viral infections therapeutic modalities peptide vaccines tcr bispecifics precision medicine innovation culture patient-centric therapies pharmaceutical r&d scientific expertise artificial intelligence information technology & services biotechnology

CD

Chris Derespino Chief Business Officer at 3T Biosciences

SN

Srikanth Nandiraju Chief Technology Officer at 1Cell.Ai Inc.

SD

Surinnder Dang Chief Business Officer at 1Cell.Ai Inc.

M

Mark Chief Executive Officer at 23Strands

IT

Ilia Tikhomirov Chief Executive Officer at 35Pharma

Outreach Guidance — research Sector

Executives like John Connolly in the research sector receive targeted outreach from sales teams, recruiters, and investors. To stand out, personalize your message with industry-specific context and a clear, specific value proposition relevant to their role at 3T Biosciences.

John Connolly's Position in the MessageCEO Database

• •John Connolly is 1 of 1 verified executive contact we track at 3T Biosciences.
• •2,871 verified executive contacts in research are in the MessageCEO database.
• •57 verified contacts work at research companies in the 30.0 employee range (same size as 3T Biosciences).

Executive contact data compiled from public business filings, LinkedIn public profiles, company press materials, and verified outbound email testing. We do not publish personal addresses or sensitive identifiers. Methodology & sources · Removal requests handled at /remove-info · Updated June 2026.

How do I reach John Connolly directly?

John Connolly's verified email address is available to MessageCEO Pro subscribers. They currently serve as Interim CEO at 3T Biosciences. Access direct contact info to skip gatekeepers and reach the decision maker.

What company does John Connolly work for?

John Connolly is Interim CEO at 3T Biosciences, a company in the research sector with 30.0 employees. The company is based in Singapore.

Can I pitch or sell to John Connolly?

As Interim CEO at 3T Biosciences, John Connolly is a key decision-maker in the research sector. MessageCEO Pro gives you verified email to reach John Connolly directly — ideal for B2B sales, partnerships, and executive recruiting.

What industry is John Connolly in?

John Connolly works in the research industry as Interim CEO at 3T Biosciences. MessageCEO provides verified contact information for executives across all major industries.

Is John Connolly's contact information verified?

Yes. MessageCEO verifies executive contact information through multiple data sources and regular validation checks. John Connolly's profile is kept up-to-date with the latest available information.

Last updated: June 21, 2026